{"id":57544,"date":"2023-06-07T22:04:14","date_gmt":"2023-06-07T20:04:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"modified":"2023-06-07T22:04:14","modified_gmt":"2023-06-07T20:04:14","slug":"atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/","title":{"rendered":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference"},"content":{"rendered":"
\n

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–$ATRA<\/a> #CART<\/a>—Atara Biotherapeutics, Inc.<\/a> (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023 at 4:00 p.m. PDT \/ 7:00 p.m. EDT.<\/p>\n

<\/a><\/p>\n

\nA live webcast of the presentation will be available by visiting the Investors and Media<\/a> section of atarabio.com<\/a>. An archived replay of the webcast will be available on the Company’s website for 30 days following the live presentation.<\/p>\n

\nAbout Atara Biotherapeutics, Inc.<\/b><\/p>\n

\nAtara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile Epstein-Barr virus (EBV) T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of non-EBV-associated liquid and solid tumors. Atara is headquartered in Southern California. For more information, visit atarabio.com<\/a> and follow @Atarabio<\/a> on Twitter<\/a> and LinkedIn<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nINVESTORS & MEDIA:<\/b>
Investors<\/b><\/i>
Eric Hyllengren 805-395-9669
\n
ehyllengren@atarabio.com<\/a><\/p>\n

\nMedia<\/b><\/i>
Alex Chapman 805-456-4772
\n
achapman@atarabio.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

THOUSAND OAKS, Calif.–(BUSINESS WIRE)–$ATRA #CART—Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-57544","6":"format-standard","7":"category-industry"},"yoast_head":"\nAtara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"THOUSAND OAKS, Calif.–(BUSINESS WIRE)–$ATRA #CART—Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-07T20:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference\",\"datePublished\":\"2023-06-07T20:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"},\"wordCount\":281,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230605005907\\\/en\\\/792504\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\",\"name\":\"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230605005907\\\/en\\\/792504\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"datePublished\":\"2023-06-07T20:04:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230605005907\\\/en\\\/792504\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230605005907\\\/en\\\/792504\\\/21\\\/Atara-Bio1_logo_300x185-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend","og_description":"THOUSAND OAKS, Calif.–(BUSINESS WIRE)–$ATRA #CART—Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 44th ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-06-07T20:04:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference","datePublished":"2023-06-07T20:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/"},"wordCount":281,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/","url":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/","name":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg","datePublished":"2023-06-07T20:04:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230605005907\/en\/792504\/21\/Atara-Bio1_logo_300x185-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/atara-biotherapeutics-to-participate-in-the-goldman-sachs-44th-annual-global-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57544","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=57544"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/57544\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=57544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=57544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=57544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}